The Impact of Immunotherapy Drugs on the Human Nervous System
DOI:
https://doi.org/10.61173/mz7bfr42Keywords:
nervous system, Alz-heimer disease, Immunotherapy drugAbstract
Immunotherapy is rapidly becoming one of the most promising directions in the modern approach to cancer treatment. CAR-T cell therapy, immune checkpoint inhibitors, monoclonal antibodies, and gene therapies have shown great potential in enhancing the quality of life of patients, through the activation of the body’s immune system against cancerous cells. In addition to cancer, immunotherapy is being tested in neurodegenerative and neuroinflammatory disorders such as multiple sclerosis and Alzheimer disease. However, these therapies entail certain risks especially with regard to the nervous system. There is increasing evidence that immunotherapies are associated with neurotoxic side effects such as neuroinflammation, encephalitis, cognitive decline and peripheral neuropathy which can greatly affect patient’s quality of life. This review focuses on the description of these immunotherapies’ mechanisms and clinical use as well as their impact on the CNS and PNS adverse effects. Measures that can help avoid these risks include precision medicine, better gene delivery vectors, and selective treatment approaches, which are very helpful in maximizing the safety and efficacy of immunotherapy. One of the critical issues of further development of these novel therapeutic interventions is the optimization of desired therapeutic outcomes and possible neurological adverse effects.
References
Journal of Clinical Pathology: Molecular Pathology, 2000, 53(3): 3.3.1 Strategies for Minimizing Neurological Adverse 173–176. Events [2] Dang J. M., Leong K. W. Natural polymers for gene delivery Several strategies have been explored to reduce the in- and tissue engineering. Advanced Drug Delivery Reviews, 2006, cidence of neurotoxic side effects. Precision medicine 58(4): 487–499. approaches involve tailoring treatment regimens based [3] Li S., Tian Z., Chen X., Wang Y., Zhang Y., Li X. Astrocytes on individual patient genetics and biomarkers, helping in the ventral hippocampus bidirectionally regulate innate and to identify patients at higher risk for adverse events and stress-induced behaviors. Advanced Science, 2024. helping to mitigate potential neurotoxicity following treat- [4] Chang A. H., Sadelain M. The Genetic Engineering of ment [17]. For example, pharmacogenomic testing can Hematopoietic Stem Cells: the Rise of Lentiviral Vectors, the guide drug selection and dosing to minimize the risk of Conundrum of the LTR, and the Promise of Lineage-restricted
neurotoxicity while maintaining therapeutic efficacy [10]. Vectors. Molecular Therapy, 2007, 15(3): 445-456. [5] Li Y., Wang H., Feng Q., Zhou Z. The genetic engineering of 3.3.2 Adjustments in Drug Delivery and Dosing hematopoietic stem cells. Nature Biotechnology, 2024. Optimizing the delivery and dosing of immunotherapeutic [6] GU Guanglei, FANG Min. Advances of monoclonal agents can also help mitigate neurotoxicity. Alternating antibodies and analysis of marketed antibody drugs. Chinese
the route of administration, such as delivering CAR-T Journal of Biotechnology, 2024, 40(5): 1431-1447. cells directly into the cerebrospinal fluid (CSF) rather than [7] Children’s Hospital of Philadelphia. (2022, May 10). Emily Dean&Francis ISSN 2959-409X Whitehead, first pediatric patient to receive CAR T-cell therapy, delivery systems. Advanced Drug Delivery Reviews, 2008, celebrates cure 10 years later. 60(12): 1123–1134. [8] Wu J. H., Zhang L. M. Advances in the application of [14] Khanal P., Patil V. S., Bhattacharya K., et al. Exploring the polygenic risk scores in psychiatric disorder research. Chinese globoid cell leukodystrophy protein network and therapeutic
Medical Abstracts: Psychiatry, 2023, 41(6): 450–455. interventions. Scientific Reports, 2024, 14: 18067. [9] Qian Y., Liu H. Q., Yang Z. Y. Evaluation of individualized [15] Byun J. I., Lee S. T., Jung K. H., et al. Effect of treatment of schizophrenia patients guided by pharmacogenomic Immunotherapy on Seizure Outcome in Patients with
testing. Chinese Journal of Psychiatry, 2023, 40(9): 123–131. Autoimmune Encephalitis: A Prospective Observational Registry [10] Zhai L., Liu T., Zhao H. Exploring the globoid cell Study. PLOS ONE, 2016, 11(1): e0146455. leukodystrophy protein network and therapeutic interventions. [16] Xiao X., Huang S., Chen S., Wang Y., Sun Q., Xu X., Li Y.
Journal of Cellular Biology, 2023, 222(7): 432–440. Mechanisms of Cytokine Release Syndrome and Neurotoxicity [11] Zhang T., Wang J., Zhao X. miR-143-3p modulates of CAR T-cell Therapy and Associated Prevention and depressive-like behaviors via Lasp1 in the mouse ventral Management Strategies. Journal of Experimental & Clinical
hippocampus. Journal of Neuroscience Research, 2023, 101(5): Cancer Research, 2021, 40: 367. 1003–1015. [17] Giavridis T., van der Stegen S. J. C., Eyquem J., Hamieh [12] Zeng W., Zhao Q., Yang X. Investigating cannabidiol’s M., Piersigilli A., Sadelain M. CAR T Cell–induced Cytokine potential as a supplementary treatment for schizophrenia: A Release Syndrome Is Mediated by Macrophages and Abated by
narrative review. ScienceDirect, 2024. IL-1 Blockade. Nature Medicine, 2018, 24(6): 731–738. [13] Wang H., Wang Z. Current status of polymeric gene
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
